Amy J. Johnson MD, PhD

Amy Johnson earned her PhD in Pharmaceutical Sciences from the University of Kentucky, studying the effects of cyclooxygenase-2 inhibitors on apoptosis pathways under the mentorship of Dr. Ching-Shih Chen.
Amy joined the Byrd Lab in 2002 as a post-doctoral researcher, examining the effects of OSU03012, a celecoxib derivative, on primary CLL cells. She also began the development and characterization of the Tcl-1 transgenic mouse model, an important tool for pre-clinical investigation of new therapeutic compounds. Amy was promoted to the position of Research Scientist in 2005, and again to Research Assistant Professor in 2007.